Invention Grant
- Patent Title: Lymphocyte function-associated antigen 3 (LFA3) variant polypeptides and methods of use thereof to treat CD2-mediated immune diseases, disorders or conditions
-
Application No.: US17035327Application Date: 2020-09-28
-
Publication No.: US12103958B2Publication Date: 2024-10-01
- Inventor: Natasha Kay Crellin , Lauren Kate Ely , Jason Robles Reyes , Chia Chi Ho , Jeffrey A. Bluestone , Eleonora Trotta , Qizhi Tang
- Applicant: PFIZER INC. , THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
- Applicant Address: US NY New York
- Assignee: Pfizer Inc.,The Regents of the University of California
- Current Assignee: Pfizer Inc.,The Regents of the University of California
- Current Assignee Address: US NY New York; US CA Oakland
- Agency: Kilpatrick Townsend & Stockton LLP
- Main IPC: C07K14/705
- IPC: C07K14/705 ; A61K39/00 ; C12N15/63 ; G01N33/50 ; G01N33/68
Abstract:
The invention provides LFA3 polypeptide molecules, e.g., variant LFA3 fusion polypeptide molecules. The invention includes uses, and associated methods of using the LFA3 polypeptide molecules.
Public/Granted literature
- US20210032308A1 LFA3 VARIANTS AND COMPOSITIONS AND USES THEREOF Public/Granted day:2021-02-04
Information query
